Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.

about

Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.

Item

http://www.wikidata.org/entity/Q47708668

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cancer/testis antigen SPATA19 ...... perplasia and prostate cancer.

@en

Cancer/testis antigen SPATA19 ...... perplasia and prostate cancer.

@nl

type

Item

label

Cancer/testis antigen SPATA19 ...... perplasia and prostate cancer.

@en

Cancer/testis antigen SPATA19 ...... perplasia and prostate cancer.

@nl

prefLabel

Cancer/testis antigen SPATA19 ...... perplasia and prostate cancer.

@en

Cancer/testis antigen SPATA19 ...... perplasia and prostate cancer.

@nl

P1476

Cancer/testis antigen SPATA19 ...... perplasia and prostate cancer.

@en

P2093

Faezahtul Arbaeyah Hussain

http://www.w3.org/2001/XMLSchema#string

Suet Kee Loo

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive immunotherapy for cancer: harnessing the T cell response

Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue

MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer

Comprehensive functional characterization of cancer-testis antigens defines obligate participation in multiple hallmarks of cancer

Proteomics. Tissue-based map of the human proteome

Complementary DNA cloning and characterization of rat spergen-1, a spermatogenic cell-specific gene-1, containing a mitochondria-targeting signal.

The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

mtDNA mutations increase tumorigenicity in prostate cancer.

European cancer mortality predictions for the year 2014.

Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression.

P304

1092-1101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/APM.12775

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

José I López

Kah Keng Wong

P577

2017-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28972294

http://www.w3.org/2001/XMLSchema#string